Confirmatory Study of DSP-5423P in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to evaluate the efficacy of DSP-5423P compared with placebo in patients with schizophrenia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sumitomo Dainippon Pharma Co., Ltd.

Criteria

Inclusion Criteria:

• Patients who have schizophrenia diagnosed by DSM-5, diagnostic criteria

• Patients who are aged 18 years or older at informed consent

• Patient understands the objectives and procedures of the study and who provide written voluntarily consent to participate in the study, etc.

Exclusion Criteria:

• Patients who fall under a contraindication listed in the blonanserin (LONASEN) package insert

• Patients with Parkinson disease

• Patients who previously received blonanserin, etc.